These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 25038567

  • 1. A new peptide (Ruviprase) purified from the venom of Daboia russelii russelii shows potent anticoagulant activity via non-enzymatic inhibition of thrombin and factor Xa.
    Thakur R, Kumar A, Bose B, Panda D, Saikia D, Chattopadhyay P, Mukherjee AK.
    Biochimie; 2014 Oct; 105():149-58. PubMed ID: 25038567
    [Abstract] [Full Text] [Related]

  • 2. A new C-type lectin (RVsnaclec) purified from venom of Daboia russelii russelii shows anticoagulant activity via inhibition of FXa and concentration-dependent differential response to platelets in a Ca²⁺-independent manner.
    Mukherjee AK, Dutta S, Mackessy SP.
    Thromb Res; 2014 Nov; 134(5):1150-6. PubMed ID: 25281435
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Two acidic, anticoagulant PLA2 isoenzymes purified from the venom of monocled cobra Naja kaouthia exhibit different potency to inhibit thrombin and factor Xa via phospholipids independent, non-enzymatic mechanism.
    Mukherjee AK, Kalita B, Thakur R.
    PLoS One; 2014 Nov; 9(8):e101334. PubMed ID: 25118676
    [Abstract] [Full Text] [Related]

  • 5. Characterization of a Kunitz-type protease inhibitor peptide (Rusvikunin) purified from Daboia russelii russelii venom.
    Mukherjee AK, Mackessy SP, Dutta S.
    Int J Biol Macromol; 2014 Jun; 67():154-62. PubMed ID: 24632346
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. At-line nanofractionation with parallel mass spectrometry and bioactivity assessment for the rapid screening of thrombin and factor Xa inhibitors in snake venoms.
    Mladic M, Zietek BM, Iyer JK, Hermarij P, Niessen WM, Somsen GW, Kini RM, Kool J.
    Toxicon; 2016 Feb; 110():79-89. PubMed ID: 26708656
    [Abstract] [Full Text] [Related]

  • 12. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
    Bhunia SS, Roy KK, Saxena AK.
    J Chem Inf Model; 2011 Aug 22; 51(8):1966-85. PubMed ID: 21761917
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Fibrin-targeted direct factor Xa inhibition: construction and characterization of a recombinant factor Xa inhibitor composed of an anti-fibrin single-chain antibody and tick anticoagulant peptide.
    Hagemeyer CE, Tomic I, Jaminet P, Weirich U, Bassler N, Schwarz M, Runge MS, Bode C, Peter K.
    Thromb Haemost; 2004 Jul 22; 92(1):47-53. PubMed ID: 15213844
    [Abstract] [Full Text] [Related]

  • 18. Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation.
    Wang W, Yuan J, Fu X, Meng F, Zhang S, Xu W, Xu Y, Huang C.
    Molecules; 2016 Apr 14; 21(4):491. PubMed ID: 27089317
    [Abstract] [Full Text] [Related]

  • 19. Characterization, mechanism of anticoagulant action, and assessment of therapeutic potential of a fibrinolytic serine protease (Brevithrombolase) purified from Brevibacillus brevis strain FF02B.
    Majumdar S, Sarmah B, Gogoi D, Banerjee S, Ghosh SS, Banerjee S, Chattopadhyay P, Mukherjee AK.
    Biochimie; 2014 Aug 14; 103():50-60. PubMed ID: 24735708
    [Abstract] [Full Text] [Related]

  • 20. Amblyomin-X having a Kunitz-type homologous domain, is a noncompetitive inhibitor of FXa and induces anticoagulation in vitro and in vivo.
    Branco VG, Iqbal A, Alvarez-Flores MP, Sciani JM, de Andrade SA, Iwai LK, Serrano SM, Chudzinski-Tavassi AM.
    Biochim Biophys Acta; 2016 Oct 14; 1864(10):1428-35. PubMed ID: 27479486
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.